Coeptis Therapeutics Holdings, Inc.

NASDAQ:COEPHealthcare · Biotechnology

Mkt Cap-

Float4.57M

Shares O/S-

Inst Own-

Dilution

Mkt Cap-

Float4.57M

O/S-

Inst Own-

Dilution

NASDAQ:COEP

MCap-

Float4.57M

O/S-

Inst Own-

Dilution

Historical Data

Date	Open	High	Low	Close	Volume

Key Metrics

Market Cap--

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership--

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

Country

IPO DateDec 17, 2020

Shares Outstanding-

Float4.57M

Company Overview

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company.

The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases.

Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology.

The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer.

In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease.

The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Leadership

Brian Cogley

Chief Financial Officer

Christine Sheehy

Vice President of Compliance and Secretary

Colleen Delaney

Chief Scientific and Medical Officer

Daniel Yerace

Vice President of Operations

Employees

Country

Sector

Healthcare

Website

coeptistx.com

Analyst Coverage

ConsensusBuy

Price Target

No price targets available

Ratings Distribution

BUY

HOLD

SELL

TOTAL1

Insider Trades

Insider	Title	Type	Shares	Value	Date
Cogley Brian	Chief Financial Officer	Option Exercise	10.0K	$105.6K	Feb 11, 2026
Cogley Brian	Chief Financial Officer	Grant/Award	12.5K	--	Feb 11, 2026
Deschamps Philippe	Director	Option Exercise	5.7K	$60.2K	Feb 11, 2026
Deschamps Philippe	Director	Grant/Award	3.3K	--	Feb 11, 2026
Calise Chris	Director	Option Exercise	5.7K	$60.2K	Feb 11, 2026
Calise Chris	Director	Grant/Award	3.3K	--	Feb 11, 2026

Shareholders

Institutional

(52)

Insiderⓘ

(16)

5%+ Owners

(2)

Unattributed (incl. retail)ⓘ

Top Shareholders

Name	Shares	%	Source
BlackRock, Inc. · also on 13F· may incl. warrants· filed Oct 2026	2.7M	5.1%	13G
BlackRock, Inc.	2.5M	--	13F
Vanguard Capital Management · filed Jul 2026	1.8M	3.4%	13G
VANGUARD CAPITAL MANAGEMENT LLC	1.7M	--	13F
GEODE CAPITAL MANAGEMENT, LLC	713.2K	--	13F
STATE STREET CORP	498.5K	--	13F
Calise Chris Director	368.7K	--	FORM 4
NORTHERN TRUST CORP	346.7K	--	13F
Mehalick David CEO and President, Director, 10% Owner	330.2K	--	FORM 4
VANGUARD PORTFOLIO MANAGEMENT LLC	303.3K	--	13F